LONDONThe UK agency that evaluates the costeffectiveness of drugs has recommended that the English health system pay for the Sovaldi hepatitis C treatment sold by Gilead Sciences Inc at a discount of roughly  from its US price Separately Gilead said Friday that it scored a key victory in securing the rights to Sovaldi after a US arbitration panel ruled in the companys favor over Roches claims on the lucrative drug